AbilityPharma’s IBRILATAZAR (ABTL0812) doubles overall survival in patients with squamous ... 05/06/2025 Healthcare Innovative drugs Advanced therapies These results support ibrilatazar as a potential backbone therapy for patients with one of the most common subtypes of... Partners - Ability Pharmaceuticals
Accelerating molecular discovery using an in silico design platform 08/07/2025 Healthcare Access to innovation Drug discovery Innovative drugs Advanced therapies Industrial biotechnology Join our free event on Tuesday, July 8th at the Parque Científico de Barcelona for an extended version of our Lunch and... Partners - SCHRÖDINGER GMBH
BioDuro hosts webinar: "Exploring Peptide In-Vitro ADME Properties – From Natural Peptides... 30/05/2025 Healthcare Drug discovery Innovative drugs Advanced therapies The webinar exploring the in-vitro ADME (Absorption, Distribution, Metabolism, and Excretion) properties of peptide... Partners - BIODURO
ORYZON awarded 13.26 million € through the first Important Project of Common European Inte... 08/05/2025 Healthcare Rare diseases Innovative drugs Oryzon to validate epigenetic agents by applying a personalized medicine approach for rare and orphan diseases. Partners - Oryzon Genomics
Theriva™ Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE ... 08/05/2025 Healthcare Access to innovation Innovative drugs Patients treated with VCN-01 (zabilugene almadenorepvec) plus gemcitabine/nab-paclitaxel standard-of-care (SoC)... Partners
I4ID 2025 Lyon Francia Del 13/11/2025 to 14/11/2025 Healthcare Innovative drugs 9th Immunotherapies and Innovations for Infectious Diseases Congress
Validation of Gate2Brain Technology in the Transport of Antibodies to the Brain Opens the ... 29/04/2025 Healthcare Innovative drugs Together, these studies reinforce the concept that advanced peptide-based brain shuttle technologies—central to the... Partners - Gate2Brain
ORYZON continues to strengthen its patent portfolio for vafidemstat 22/04/2025 Healthcare Innovative drugs Oryzon secures new patents in Europe and Japan for vafidemstat, extending protection until 2040 for ADHD and autism... Partners - Oryzon Genomics
ORYZON announces first patient dosed in NCI-sponsored Phase I/II clinical trial of iadadem... 15/04/2025 Healthcare Innovative drugs Oryzon Genomics has launched a clinical trial in the U.S. to evaluate for the first time the combination of its... Partners - Oryzon Genomics
Telum Therapeutics, Complutense University of Madrid and Carlos III Health Institute disco... 03/04/2025 Healthcare Innovative drugs It was funded by Spanish Ministry of Science, Innovation and Universities (MCIN) and the European Union through the... Partners - TELUM THERAPEUTICS
